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The International Symposium on Intensive Care and
Emergency Medicine continues to grow every year, with in
excess of 4000 attendees. With six parallel sessions for four
frenetic days, it covers all aspects of critical care from a
variety of perspectives. This year, as in previous years, the
symposium was marred only by the perennial problems of
overcrowding and audiovisual glitches. The organisers, to
their credit, had attempted to counter the problems with use
of lecture rooms beyond the congress centre. Sadly,
however, many sessions remained oversubscribed. Web
casting of lectures to second venues has successfully been
employed elsewhere and would greatly enhance this, already
pre-eminent, international critical care symposium.
Opening session
As is traditional, the exuberant and charismatic Jean Louis
Vincent (Brussels, Belgium) opened this year’s meeting,
espousing ‘The great step forward’. His personal tour
through the events of the past 12 months focused on the first
Hippocratic tenet: ‘first, do no harm’. Iatrogenic injury was his
major theme, be it by the use of excessive tidal volume [1],
excessive sedation [2,3], delayed resuscitation [4], poor
glycaemic control [5], inadequate renal replacement [6], or
failure to cool the brain post anoxic injury [7,8]. He went on,
however, to caution against the vagaries of fashion. Despite
negative studies, he argued, there is still a place for the
pulmonary artery catheter [9], for albumin [10,11] and for
dopamine [12], but their use must be intelligently tempered.
Two items of breaking news were also raised. First, the
recent sepsis consensus conference may shortly result in the
abandonment of the Systemic Inflammatory Response
Syndrome (SIRS) criteria in favour of PIRO [13] (see also
[14]). Second, participation in the up and coming Sepsis
Occurrence in the Acutely Ill Patient (SOAP) study
(1–15 May 2002) was promoted to all participants.
Jean Carlet (Paris, France) and Derek Angus (Pittsburgh, PA,
USA) then presented a report from the presymposium round-
table conference, ‘Surviving intensive care’. To date, the vast
majority of intensive care unit (ICU) interventional studies
have used short-term morbidity and mortality as outcome
measures. However, there is an increasing desire and
necessity to establish the long-term outcomes. What little
evidence does exist suggests that survivors of critical illness
have diminished life expectancy, functional limitations,
neuropsychological morbidity and, unsurprisingly, a reduced
quality of life [15–20]. The round-table group reached the
following conclusions:
• Established and evolving best practice has identified, and
will continue to identify pre, intra and post ICU causes
and modifiers of a poor long-term outcome. In particular,
preventing neuro-musculo-skeletal sequelae by ensuring
early and successful feeding, coupled with a proactive
approach to physiotherapy and rehabilitation, is essential.
• Historical precedents should remind us that good short-
term outcomes can result in poor long-term outcomes
(e.g. milrinone in the treatment of chronic congestive
cardiac failure). Long-term follow up as routine practice in
all interventional trials is thus to be encouraged and
should have a place in everyday practice. However, this is
almost certainly beyond the scope of intensivists, hence
creative partnerships between ICUs, referring and primary
care clinicians need to be forged.
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Jean Mira (Paris, France) gave a whirlwind tour through the
topic of genetic predisposition as it genuinely begins to
impact at the bedside. Polymorphisms in both the promoters
and the coding regions of specific genes, affecting the
quantity and quality, respectively, of the gene product, have
now been identified that confer a quantifiable risk of disease
severity and fatal outcome in critical illness [21–27]. With the
rapid and dramatic advances in nanochip and microarray
technology, bedside genotyping is set to become a reality
over the next few years [28]. This raises the possibility of
designing specific therapeutic cocktails to counter the
susceptibilities identified by genotyping. However,
enthusiasm for this science fiction approach must be
tempered by the enormous gulf between identifying
genotypic risk and successful development of therapeutic
interventions. The even thornier issues of the socioeconomic
ramifications of genotype profiling need legislative
consideration now if the worst elements of eugenic prejudice
are to be avoided.
Steven Opal (Pawtucket, RI, USA) gave an overview of the
complex integration between dysregulation of the innate
immune and coagulation systems [29]. Although a number of
recent discoveries have illuminated this field, it appears to
have been around for at least 800 million years [30]! The
relevance of this subject relates to the success of
recombinant human activated protein C in severe sepsis [31]
in contrast to the failure of antithrombin III [32].
Greet Van den Berghe (Leuven, Belgium) presented results
from the landmark intensive insulin study [5]. She reminded the
audience that although the renal glucose threshold is in the
order of 12 mmol/l, other tissues (in particular, the lung) might
exhibit thresholds as low as 8 mmol/l. The intensive group in
this study demonstrated not only a much lower incidence of
multiorgan failure and nosocomial infection, but demonstrated
decreased polyneuropathy and mortality. Whether this is the
effect of higher doses of insulin or lower levels of blood
glucose remains speculative. What is clear is that high insulin
requirements are associated with a worse prognosis. This
study also serves to demonstrate the vital importance of
attending to routine care, as this can achieve benefits equal to
or greater than novel therapies, and at a fraction of the cost.
Peter Andrews (Edinburgh, UK) presented the evidence for,
and mechanisms by which, isolated brain cooling can be
achieved [33]. This work may help explain the contradictory
results from trials of systemic cooling following neurological
injury [7,8,34,35].
The final two lectures in this session covered the issues of
terrorist attacks and mass casualty response. The lessons
learned from recent and ongoing world events are that
education, preparedness and practice [36] are the vital
elements in meeting the harrowing challenges presented by
such events.
Early haemodynamic stabilisation
In this enthusiastically attended session, chaired by
Christopher Doig (Calgary, Canada) and Daniel De Backer
(Brussels, Belgium), some of the more practical issues
concerning the care of the haemodynamically unstable
patient were discussed.
Jesse Hall (Chicago, IL, USA) opened the session stressing
that by the bedside, as yet, we are only able to assess global
oxygen delivery and consumption and to monitor surrogates
of tissue hypoxia. We presently have no direct means of
assessing tissue perfusion, let alone specific vascular beds.
However, Jesse Hall questioned the practice of oxygen
delivery/consumption goal-directed therapy in the critically ill
patient, citing a number of papers demonstrating
disappointing or adverse outcomes [37–39].
In firm and eloquent rebuttal to this, Robert Grounds
(London, UK) presented the evidence for goal-directed
therapy, particularly with respect to the high-risk surgical
patient. He suggested that there is now an increasingly
convincing body of evidence to support the practice of
preoperative ‘optimisation’ in the form of fluid and inotropic
manipulation of the circulation to improve cardiac output and,
hence, tissue oxygen delivery. A number of studies over the
past decade have shown impressive reductions in
postoperative mortality by employing this technique [40–43].
It was a treat to hear a landmark paper presented by its first,
now famous author, Emmanuel Rivers (Detroit, MI, USA) [4].
In studying a group (n = 263) of patients admitted to the
emergency room with severe sepsis and septic shock,
subjects were randomised to either early goal-directed
therapy (treatment group) or standard therapy (control). They
used traditional resuscitation end points, blood pressure,
central venous pressure and urine output, as well as central
venous saturation, to target therapy. Results were striking, to
say the least, with 60-day mortality of 44.3% and 56.9% in
the treatment and control groups, respectively. Food for
thought that 6 hours of simple resuscitation, if prompt, can
have such an impact on the mortality rate in severe sepsis
without recourse to novel and massively expensive
pharmacological strategies.
Finally in this session, Konrad Reinhart (Jena, Germany)
reminded us of the potential use of central venous
saturations as a guide to therapy, thereby possibly avoiding
the need for pulmonary artery catheterisation [44].
Noninvasive mechanical ventilation
The session on noninvasive ventilation (NIV) proved popular. It
summarised the research in this field, discussed various
practical problems and suggested remedies. Umberto Meduri
(Memphis, TN, USA) divided the evidence for NIV in acute
respiratory failure on the basis of timing into early (to prevent
intubation), established (as an alternative to intubation),Critical Care    June 2002 Vol 6 No 3 Ball et al.
resolving (to wean from mechanical ventilation), and
postextubation (to prevent reintubation). Overall, the eight
randomised studies for patients with chronic obstructive
pulmonary disease showed significant reductions in intubation
requirements and mortality, when used early. The evidence for
early intervention in patients without chronic obstructive
pulmonary disease and in the remaining time frames suggested
favourable outcomes, but more studies are required.
An analysis of the need for intubation following NIV showed
that mask intolerance resulted in 11% of cases [45]. Paolo
Navalesi (Pavia, Italy) reiterated that faces are all different and
there was therefore a need for a wide variety of facemasks
for the individual to try, if NIV was to be successful.
The problem of gas leaks was discussed by Robert
Kacmarek (Boston, MA, USA), and the mannequin model of
Schettino and colleagues [46] highlighted the fact that
inappropriately high pressure support can greatly exacerbate
leaks. To prevent rebreathing, Robert Kacmarek stressed the
need for adequate positive end-expiratory pressure and that
the exhalation port should be ideally placed in the facemask
[47]. Laurent Brochard (Creteil, France) continued on the
subject of leaks and suggested the use of ventilators, which
are capable of monitoring inspiratory and expiratory tidal
volumes early in acute respiratory failure, to identify
insufficient ventilation as a consequence of leaks.
Asynchrony as a result of leaks may be aided by the use of
time-cycled ventilation, although this will obviously not
resolve any leaks. Finally, the addition of helium to NIV may
reduce the work of breathing, although limited space may
prevent placement of the large tanks of helium required, and
only certain ventilators are able to work with helium.
Massimo Antonelli (Rome, Italy) reviewed the trials for the use
of NIV in acute lung injury/acute respiratory distress
syndrome (ALI/ARDS). He concluded that the present
favourable evidence should not be interpreted to support the
extensive use of NIV in ALI/ARDS, but rather it should be
used to design a randomised, controlled trial for NIV early in
ALI/ARDS.
Finally, Phillipe Jolliet (Geneva, Switzerland) concluded that
there was no solid evidence to support the use of NIV in
community acquired pneumonia except in the subgroups of
patients with chronic obstructive pulmonary disease and in
the immunosuppressed. In all groups, however, NIV improves
blood gases in community acquired pneumonia, NIV does not
increase nursing workload in experienced units, no adverse
effects have been demonstrated and, importantly, intubation
is not delayed since it occurs early in community acquired
pneumonia if required.
PEEP recruitment: do we understand it?
An afternoon was devoted to answering this question and,
consequently, there was a good deal of overlap between
speakers. All agreed that recruitment was necessary to
establish alveolar patency in all recruitable lung zones and to
therefore avoid repeated opening/closing of lung units with
consequent inflammation and lung injury.
Jordi Mancebo (Barcelona, Spain) highlighted that
recruitment is a time-dependent process, and that
approximately 40 s is required during a sustained high-
pressure (Pmax =4 0c m H 2O) recruitment manoeuvre. Other
recruitment manoeuvres include sighs, progressive PEEP
(with fixed peak pressure and tidal volume), and repositioning
(e.g. prone position, lateral position), although how PEEP is
best selected following recruitment is not known. Biological
variable ventilation (i.e. varying tidal volume as would happen
physiologically) is an interesting new concept. It has been
shown to improve recruitment and to reduce interleukin-6
levels, and therefore may reduce lung injury. Prof. Kacmarek
(Boston, MA, USA) summarised that pressure/volume curve
analysis is no longer considered clinically useful in
determining best PEEP since methodology has not been
standardised for curve derivation, and the upper inflection
point and point of maximum curvature may be affected by
different methodologies.
Fernando Suarez (Madrid, Spain) gave a very clear
presentation of his work investigating oxygenation (PaO2/FiO2
ratios) versus lung mechanics (static compliance) in
identifying best PEEP. Using a decremental PEEP trial (i.e.
following recruitment), oxygenation and compliance were
improved in comparison with an incremental PEEP trial (i.e.
prior to recruitment), although optimal positions for
oxygenation and compliance were at different positions on
this curve. We are consequently none the wiser at predicting
the point to set PEEP where lung overdistension and lung
collapse are at a minimum. The moderators (Michael Pinsky,
Pittsburgh, PA, USA, and Antonio Pesenti, Monza, Italy)
commented that PaO2/FiO2 ratios may not be the best
measure of shunt since PEEP can cause ventricular
dysfunction, which affects shunt. Finally, Laurent Brochard
(Creteil, France) discussed the influence of tidal volume on
alveolar recruitment [48], and suggested that PEEP may need
to be increased if using protective low tidal volume ventilation.
Although this session left the audience none the wiser in
clinically determining best PEEP, the evidence to date
suggests that the lung should be kept open to prevent
ventilator-induced lung injury, although to achieve this we
may be simultaneously subjecting the lung to overdistension
and ventilator-induced lung injury. Finally, it was commented
that the NIH PEEP trial had recently been abandoned since
initial analysis had shown no effect, and because subsequent
power analysis had revealed that the numbers of patients
therefore required to show an effect would be massive.
Perhaps the high PEEP was not applied appropriately since
the method of recruitment in the decremental PEEP trial was
not used in this study.High-frequency ventilation: pro/con debate
A very amusing debate followed, with Arthur Slutsky
(Toronto, Canada) directing his attack at ridiculing Robert
Kacmarek (Boston, MA, USA) with the use of surreptitiously
obtained holiday photographs of the latter, to remove his
credibility as a speaker! This left Arthur Slutsky with very little
time to discuss the evidence that high-frequency ventilation
(HFV) is beneficial.
Robert Kacmarek led a strong defence and showed that
animal studies comparing HFV with conventional ventilation
(CV) had utilised a nonprotective lung strategy in the CV arm,
and so comparison was not valid. Similarly, human data from
the second multicentre oscillatory ARDS trial (MOAT II)
showed a trend towards a reduction in mortality at 90 days,
although the study was not powered to investigate this.
However, the CV group in this trial received mean tidal
volumes of 10.2 ml/kg, which more recent evidence [1]
suggests is too large and hence detrimental.
Following the debate, both speakers agreed that HFV and
CV are equally efficacious, although HFV should theoretically
be superior. The benefits seen in the neonatal ICU (although
the incidence of intraventricular haemorrhage was higher in
this particular HFV population when compared with CV) may
be the result of being able to use higher frequencies
compared with adults. In the adult ICU, HFV frequencies are
halved to enable adequate carbon dioxide clearance.
Renal failure
A broad range of subjects relating to renal failure were
touched on, and the usual questions when considering renal
failure in the critically ill (namely choice of renal replacement
therapy [RRT] modality, type of membrane and adequacy)
were raised.
Daniel Traber (Galveston, TX, USA) entertained us with an
overview of the kidney’s response to sepsis, which led us
into the debate regarding modality. The overall consensus
seemed to be in favour of continuous treatments, although no
major antagonists were present: perhaps the battle has been
won. As John Kellum (Pittsburgh, PA, USA) pointed out: are
continuous therapies better? Probably!
There were the usual statistics with regard to mortality of
acute renal failure. It is important to remember, however, that
single-organ acute renal failure carries a mortality <8%. The
≥50% mortality reflects the overall picture of multiorgan
failure of which acute renal failure is a part.
Kurt Lenz (Linz, Austria) discussed the hepatorenal syndrome
and cemented the view that this remains a diagnosis of
exclusion. Finally, Claudio Ronco (Vicenza, Italy) outlined the
concept, beloved to nephrologists, of adequacy. It was one
of the few times I have heard Kt/V (the RRT clearance of
urea, in other words a measure of the adequacy of RRT [49])
discussed outside a renal ward, and it perhaps may have
helped clear up some misconceptions with regard to RRT.
Ronco also gave an excellent plenary lecture on
extracorporeal support in sepsis, although unfortunately the
jury remains out on this treatment. As he said: until the
randomised, controlled trial is carried out, we will not know.
Acid–base
David Bennett’s (London, UK) honesty must be commended
in suggesting that strong ion difference and strong ion gap
are difficult to comprehend. In fact, his explanation of the
subject was extremely clear. Recent work at his hospital had
unfortunately not found strong ion difference a useful
prognostic marker for patients admitted to the ICU.
John Kellum (Pittsburgh, PA, USA) showed that acidosis
worsens shock in an animal model, and that acidosis is
proinflammatory in cultured lung macrophages. The
implication is therefore that, under most conditions, acidosis
should be avoided in the critically ill. This does not
necessarily, however, imply that mild acidosis requires
correction with sodium bicarbonate, not least as the
controversies surrounding this intervention remain [50].
Head trauma
Andrew Maas (Rotterdam, The Netherlands) discussed the
pros and cons of using cerebral perfusion pressure, blood
flow or oxygen to target therapy in the management of head
trauma. Oxygen-targeted therapy using jugular venous
oxygen saturation monitoring was appealing, although this
has not yet been validated. Other treatment modalities
presented by other speakers (e.g. raising cerebral perfusion
pressure, hypothermia) have unfortunately continued to show
disappointing results in the management of head trauma.
Andrew Maas ended the session, however, by explaining that
these treatments may in fact be beneficial but the outcome
assessments were invalid. In many of these trials, the
Glasgow Outcome Scale was used and outcome was
dichotomised into good/poor, when in fact this is a four-point
scale. If reanalysed using a sliding-dichotomised method, as
previously used in many of the stroke trials, then many of the
head trauma studies were grossly under-powered.
Transfusion
This excellent session covered all aspects of the increasingly
muddy waters surrounding the issues of red cell transfusion
in resuscitation and critical illness. With the landmark
Canadian study of restricted transfusions in critically patients
[51], the possibility of disease transmission (in particular,
new-variant Creutzfeldt-Jacob Disease) and the simple
economics of demand outstripping supply, the questions
regarding what you should transfuse and when it should be
transfused have escalated.
The effects of storage on red blood cell (RBC) deformability
and oxygen dissociation are well established [52–55]. What
Available online http://ccforum.com/content/6/3/264happens to such cells once in the circulation remains more
contentious. Timothy Walsh (Edinburgh, UK) presented the
preliminary results of a study in which the haemoglobin
concentration of critically ill patients was closely monitored
peritransfusion. His group found that the haemoglobin
concentration returned to baseline (transfusion threshold)
within 48 hours. Further investigations suggest that, despite
this and the gross morphological abnormalities of the stored
RBCs, these cells persist in the circulation well beyond this
48-hour period. He stressed that the haemoglobin
concentration and RBC mass do not have a linear
relationship, especially in critically ill patients who tend to
exhibit low mean corpuscular haemoglobin concentration.
Timothy Walsh concluded by reminding the audience that the
risk–benefit profile of top-up transfusion has yet to
established.
The immunosuppressive effects of allogenic RBC transfusion
are well established [56,57]. One of the major contributors is
thought to be the presence of allogenic leukocytes. Indeed,
the positive findings of the Canadian restricted transfusion
study [51] have been attributed, at least in part, to the
reduced dose of allogenic leukocytes in the restricted group.
Hence the widespread interest in investigating the effects of
universal leukocyte depletion. Such a strategy appears to
have benefits, although these may depend on whether the
removal is performed prestorage or pretransfusion [58]. Jean-
François Baron (Paris, France) presented the results of the
recently published French study, which investigated the
incidence of postoperative infections in patients undergoing
abdominal aortic aneurysm repair who received
leukodepleted or nonleukodepleted blood transfusions [59].
Although no statistically significant different was found
between the two groups, the study was grossly
underpowered. The results of a larger Canadian study are
keenly awaited.
Alternative strategies to packed RBC transfusion were also
discussed. Howard Corwin (Lebanon, USA) presented the
case for routine use of recombinant erythropoietin [60,61]. In
essence, the evidence to date demonstrates that
erythropoietin significantly reduces transfusion requirements
but has failed to show a morbidity or mortality benefit.
Intriguingly, erythropoietin appears to have extensive
neuroprotective properties, and human trials in a variety of
acute neurological insults are eagerly awaited [62].
Marcos Intraglietta (La Jolla, CA, USA) presented an
emerging alternative hypothesis to the dogma of maintaining
oxygen delivery by maintaining oxygen carrying capacity (i.e.
RBC transfusion). He presented the evidence that
maintenance of blood viscosity and hence functional capillary
density is the critical factor [63]. He went on to present his
and others work on PEGylated haemoglobin solution, which
not only increases blood viscosity, but also is the first free
haemoglobin solution to exhibit near identical oxygen
dissociation characteristics to RBCs. PEGylated
haemoglobin solution consequently does not induce the
limiting hypertension and microvascular pathophysiology
associated with other free haemoglobin solutions [64–66].
In the context of acute, severe/unstoppable haemorrhage,
Mauricio Lynn (Miami, FL, USA) presented data that
recombinant activated factor VII offers a new life-saving
intervention [67–69]. Indeed, it seems probable that this
drug will be the subject not only of clinical studies into the
treatment of haemorrhage, but may also have a role in
immune modification as it avidly binds tissue factor.
Recombinant activated factor VII is thus being investigated
as a carrier molecule to neutralise this major proinflammatory
mediator.
Conclusion
As the preceding sections hopefully demonstrate, the breath
and depth of this year’s symposium, as in previous years, left
attendees spoilt for choice and, potentially at least,
exhausted. Undoubtedly, the International Symposium on
Intensive Care and Emergency Medicine will continue to
expand both as an educational forum and as a research
forum, creating ever greater challenges to the programme
designers.
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